Market revenue in 2022 | USD 17.3 million |
Market revenue in 2030 | USD 36.7 million |
Growth rate | 9.9% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52.02% in 2022. Horizon Databook has segmented the Sweden non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
The market in this nation is anticipated to grow at a rapid pace during the forecast period due to a growing incidence of Down syndrome, government support, as well as consumer awareness. NIPT, unlike other genetic tests for children and adults, is widely done and recommended in private clinics in Sweden, resulting in coverage by both private and public insurance systems. Thus, it will increase the demand for NIPTs and further fuel the market.
According to a study, Medicare Health Maintenance Organization (HMO) offers a higher frequency of reimbursement compared to Private HMOs. Greater frequency and higher reimbursement are related to younger demographics (patients below 65 years). Medicare HMO pays more frequently and generously than private payers for patients over the age of 65 years.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Sweden non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account